Doug Williams

Doug Williams

Doug Williams, head of Research and Development at Biogen Idec, discusses remyelinating agents, Alzheimer's disease drugs and gene therapy. Since Doug Williams signed on as Executive Vice President of Research and Development at Biogen Idec in 2011, the company has had a string of successes. It...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Drug discovery 2014-12, Vol.13 (12), p.880-881
Hauptverfasser: Williams, Doug, Mullard, Asher
Format: Artikel
Sprache:eng
Schlagworte:
631/154/2426
631/378/1689
692/308/153
Alzheimer Disease - drug therapy
Alzheimer Disease - genetics
an-audience-with
Biomedicine
Biotechnology
Cancer Research
Drug Industry - trends
Genetic Therapy - trends
Humans
Medicinal Chemistry
Molecular Medicine
Multiple Sclerosis - drug therapy
Multiple Sclerosis - genetics
Pharmacology/Toxicology
Research - trends
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Doug Williams, head of Research and Development at Biogen Idec, discusses remyelinating agents, Alzheimer's disease drugs and gene therapy. Since Doug Williams signed on as Executive Vice President of Research and Development at Biogen Idec in 2011, the company has had a string of successes. Its oral multiple sclerosis drug Tecfidera has snagged a spot as one of the best launches ever, with well over US$1 billion in its first full four quarters of sales, and a recent pair of long-acting haemophilia drug approvals are set to shake up the haematology market. Future growth could come from remyelinating agents, Alzheimer's disease drugs and gene therapy, Williams tells Asher Mullard.
ISSN:1474-1776
1474-1784
DOI:10.1038/nrd4496